代理店さま専用ページ

English

トップページ » 貿易事業 » ライフケア » 食品・健康＆美容商品» Probiotical プロバイオティカル イタリアの多様な生菌剤の世界的メーカー（消化器系)

Probiotical プロバイオティカル - 多様な生菌剤の世界的メーカー

プロバイオティカル社の多様な菌株と領域別菌株

BIFIDOBACTERIUM STRAINS
ビフィズス菌株		 消化器系 骨と髪の健康 神経系
LACTOBACILLUS STRAINS
乳酸菌株		 免疫と
アレルギー		 心血管代謝 アイケア
STREPTOCOCCUS THERMOPHILUS
連鎖球菌サーモフィルス		 皮膚系 婦人系 スポーツ
BLENDS
ブレンド		 健康な老化 泌尿器系 オーラルケア

消化器系

赤ちゃんの疝痛

Bifidobacterium breve BR03™ (DSM 16604)
Bifidobacterium breve B632™ (DSM 24706)
BIFIBABY™
機能性
  • ガス性疝痛
  • 胃腸症状の予防
  • 小児と乳児の腸内菌叢のバランスを整える
  • 腹痛のある乳児から分離された腸内細菌およびその他の大腸菌群の抑制
臨床試験における１日の投与量
 1, 2, 3) BR03 100 million CFU + B632 100 million CFU
 *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態 ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Bona G. et al. The association of BR03 and B632 is effective to prevent colics in bottle-fed infants: a pilot, controlled, randomized and double blind study. Published in J Clin Gastroenterol, 2016.
  2. Aloisio I. et al. Three-Month Feeding Integration with Bifidobacterium Strains Prevents Gastrointestinal Symptoms in Healthy Newborns. Frontiers in Nutrition, May 2018, art. 39.
  3. Mogna L. et al. Capability of the Two Microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to Colonize the Intestinal Microbiota of Children J Clin Gastroenterol, 2014. Suppl. 1, November/December, Vol. 48.
 インビトロ研究
  1. Simone M. et al. The Probiotic Bifidobacterium breve B632 Inhibited the Growth of Enterobacteriaceae within Colicky Infant Microbiota Cultures.
  2. BioMed Research International 1-6, 2014. b)Aloisio I. et al. Characterization of Bifidobacterium spp. strains for the treatment of enteric disorders in newborns. Appl Microbiol Biotechnol 2012, 96:1561–1576.
  3. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
  4. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl.S29-32.
  5. Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008. (DSM 20074 was re-deposited as 22106).
 セリアック病における本ブレンドの他の研究についてはPDF 11ページを、小児肥満とインスリン抵抗性における研究については PDF 44ページを参照してください。

Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106)
機能性
  • ガス状疝痛
  • 毒素原性 O157:H7 を含む大腸菌の抑制
  • 疝痛のある乳児から分離された肺炎桿菌およびさまざまな大腸菌群の抑制
可能形態 ブレンド原体、あるいは製剤
学術サポート
 インビトロ研究
  1. Savino F. et al. Antagonistic effect of Lactobacillus strains against gasproducing coliforms isolated from colicky infants. BMC Microbiology 2011, 11:157.
  2. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012;46 Suppl.S29-32.
  3. Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106): An Innovative Strategy to Possibly Counteract Such Infections in Humans?
    J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S136-S139.
  4. Savino F, et al. Antagonistic effect of Lactobacillus strains against gasproducing coliforms isolated from colicky infants. BMC Microbiol. 2011 Jun 30;11:157.


セリアック病

Bifidobacterium breve BR03™ (DSM 16604)
Bifidobacterium breve B632™ (DSM 24706)
CELIAFLORA™ JUNIOR
機能性
  • セリアック病における腸の炎症と小胞体ストレスの軽減
臨床試験における１日の投与量
 1) BR03 100 million cells + B632 100 million cells
 2, 3, 4) BR03 1 billion CFU + B632 1 billion CFU
 *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態 ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Mogna L. et al. Capability of the two microorganisms B632 and BR03 to colonize the intestinal microbiota of children. J Clin Gastroenterol. 2014; 48 Suppl:S37-39.
  2. Klemenak M. et al. Administration of decreases the production of TNF-α in children with celiac disease. Dig Dis Sci (2015).
  3. Quagliariello A. et al. Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: A Pilot Study. Nutrients. 2016 Oct 22;8(10). pii:E660.
  4. Primec M. et al. Clinical intervention using Bifidobacterium strains in celiac disease children reveals novel microbial modulators of TNF-α and short-chain fatty acids. Clinical Nutrition 2018, 1-9.
  5. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
 インビトロおよび動物試験
  1. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl.S29-32.
  2. Ferrari E, et al. Probiotics Supplements Reduce ER Stress and Gut Inflammation Associated with Gliadin Intake in a Mouse Model of Gluten Sensitivity. Nutrients. 2021 Apr 7;13(4):1221.
 乳児疝痛に関する研究についてはPDF 10ページを、小児肥満とインスリン抵抗性の研究については PDF　44ページを参照してください。

Lactiplantibacillus plantarum LP14 (DSM 33401)
(旧名 Lactobacillus plantarum)
Lacticaseibacillus paracasei LPC09 (DSM 24243)
(旧名 Lactobacillus paracasei)
Lacticaseibacillus rhamnosus LR04 (DSM 16605)
(旧名 Lactobacillus rhamnosus)
CELIAFLORA™ ADULTS
機能性ƒ
  • セリアック病における腸の炎症と小胞体ストレスの軽減
可能形態ブレンド原体、あるいは製剤
学術サポート
 膜の完全性に関する内部データはご要望に応じて入手可能です。

 インビトロおよび動物試験
  1. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216
  2. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl.S29-32.
  3. Chamignon C et al. Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various Lactobacillus Strains. Microorganisms. 2020 Jul 15;8(7):1053.
  4. Ferrari E, et al. Probiotics Supplements Reduce ER Stress and Gut Inflammation Associated with Gliadin Intake in a Mouse Model of Gluten Sensitivity. Nutrients. 2021 Apr 7;13(4):1221.


IBD / 腹部手術 / 腸の調整

Lactiplantibacillus plantarum LP01™ (LMG P-21021)
(旧名 Lactobacillus plantarum)
Lactococcus lactis LLC02 (DSM 29536)
Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106)
FLOR-EN™ ADULTS
機能性ƒ
  • IBD (炎症性腸疾患) 患者、腹部手術を受けた患者、および結腸内視鏡検査後の患者における腸内毒素症を抑制し、腹痛や膨満感などの症状を改善。
臨床試験における１日の投与量
 1, 2, 3) LP01 1 billion cells + LLC02 800 million cells + LLD01 200 million cells
 *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態 ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Bonavina L, Arini A, Ficano L, Iannuzziello D, Pasquale L, Aragona SE, Ciprandi G, On Digestive Disorders ISG. Abincol® (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01), an oral nutraceutical, pragmatic use in patients with chronic intestinal disorders. Acta Biomed. 2019 Jul 10;90(7-S):8-12.
  2. Bonavina L, Arini A, Ficano L, Iannuzziello D, Pasquale L, Aragona SE, Ciprandi G, On Digestive Disorders ISG. Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01). Acta Biomed. 2019 Jul 10;90(7-S):18-23.
  3. Bonavina L, Ariani A, Ficano L, Iannuzziello D, Pasquale L, Aragona SE, Drago L, Ciprandi G, On Digestive Disorders ISG. Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation. Acta Biomed. 2019 Jul 10;90(7-S):13-17.
 インビトロ研究
  1. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012;46 Suppl.S29-32.
  2. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.
  3. Amoruso A. et al. (2019) A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 7:214.
 咽頭扁桃炎、喉頭気管炎、鼻副鼻腔炎、上気道疾患、中耳炎に関する研究については、PDF 29 ページを参照してください。


IBD / 腸炎

Lactiplantibacillus plantarum LP14 (DSM 33401)
(旧名 Lactobacillus plantarum)
Lacticaseibacillus paracasei LPC09 (DSM 24243)
(旧名 Lactobacillus paracasei)
Lacticaseibacillus rhamnosus LR04 (DSM 16605)
(旧名 Lactobacillus rhamnosus)
CELIAFLORAN™ IBD ADULTS
機能性ƒ
  • 炎症と小胞体ストレスを軽減。
  • タイトジャンクションタンパク質の発現の増加と回復。
  • IBDにおけるアポトーシス細胞死とフェロトーシス細胞死の両方に対抗。
可能形態 ブレンド原体、あるいは製剤
学術サポート
 インビトロ及び動物試験
  1. Monzani R, et al. The Gut-Ex-Vivo System (GEVS) Is a Dynamic and Versatile Tool for the Study of DNBS-Induced IBD in BALB/C and C57BL/6 Mice, Highlighting the Protective Role of Probiotics. Biology (Basel). 2022 Oct 27;11(11):1574
 膜の完全性に関する内部データはご要望に応じて入手可能です。
 セリアック病に関して発表された研究については、PDF 11 ページを参照してください。


IBD / 便秘

Lactiplantibacillus plantarum LP01™ (LMG P-21021)
(旧名 Lactobacillus plantarum)
機能性
  • 便秘
  • 腸管通過
  • リーキーガット
  • 大腸菌およびその他の病原体の抑制
臨床試験における１日の投与量
 1) 10 billion CFU
 *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　単体原体、ブレンド原体、あるいは製剤]
学術サポート
 ヒト臨床試験
  1. Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly. CIBUS, 2005; 1(1):23-30.
 インビトロ研究
  1. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
  2. Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008.
  3. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.
  4. Amoruso A. et al. (2019) A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 7:214.
 抗炎症活性と腸管バリアに関するさらなる内部データは、ご要望に応じて入手可能です。

Bifidobacterium animalis subsp. lactis BS01™ (LMG P-21384)
BIFIFIBER®
機能性
  • 便秘
  • 腸管通過
  • 胃腸の不快感の軽減
  • リーキーガット
臨床試験における１日の投与量
 1) 5 billion CFU 2) 10 billion CFU 3) 5 billion CFU
 4) 5 billion or 1 billion cells
 *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Del Piano M. et al. The use of probiotics in healthy volunteers with evacuation disorders and hard stools. A double blind, randomized, placebocontrolled study. J Clin Gastroenterol, 2010; 44(8):S30-34.
  2. Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly. CIBUS, 2005; 1(1):23-30.
  3. Dimidi E. et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;100:1075–84.
  4. Del Piano M. et al. Comparison of the Kinetics of Intestinal Colonization by Associating 5 Probiotic Bacteria Assumed Either in Microencapsulated or in a Traditional, Uncoated Form. J Clin Gastroenterol 2012;46:S85-S92.

Bifidobacterium breve BR03™ (DSM 16604)
機能性
  • 便秘
  • 腸管通過
  • 抗炎症
  • 胃腸の不快感の軽減
  • 病原性大腸菌の抑制
臨床試験における１日の投与量
 1) 10 billion CFU 2) 5 billion CFU or 1 billion cells
 *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly CIBUS, 2005; 1(1):23-30.
  2. Del Piano M. et al. Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains. J Clin Gastroenterol. 2010; 44 Suppl 1:S42-6.1) Del Piano M. et al. The use of probiotics in healthy volunteers with
 インビトロ研究
  1. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012;46 Suppl.S29-32.
  2. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
  3. Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008. (DSM 20074 was re-deposited as 22106).
  4. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
  5. Amoruso A. et al. (2019) A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 7:214.

Bifidobacterium longum BL03 (DSM 16603)
Lactiplantibacillus plantarum LP01™ (LMG P-21021)
(旧名 Lactobacillus plantarum)
Bifidobacterium animalis subsp. lactis BS01™ (LMG P-21384
Bifidobacterium adolescentis BA02 (DSM 18351)
(旧名 ALB 1)
Bifidobacterium breve BR03™ (DSM 16604)
機能性
  • 便秘
  • 腸管通過
臨床試験における１日の投与量
 1) 10 billion CFU
 *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly (BL03, LP01, BS01, LR05, BA02 and BR03 seperately). CIBUS, 2005; 1(1):23-30.
 インビトロ研究
  1. Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008. (DSM 20074 was re-deposited as 22106).
  2. >Rossi M. et al. fermentation of fructooligosaccharides and inulin by Bifidobacteria: a comparative study of pure and fecal cultures (BA02). Applied and Environmental Microbiology, 2005;71(10):6150-6158.
  3. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.
  4. Amoruso A. et al. (2019) A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 7:214.
  5. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
  6. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl.S29-32.

Lactiplantibacillus plantarum LP01™ (LMG P-21021)
(旧名 Lactobacillus plantarum)
Bifidobacterium breve BR03™ (DSM 16694)
BIFICOL®
機能性
  • IBS
  • 便秘
  • 腸管通過
  • 胃腸の不快感の軽減
  • 炎症の軽減
  • 毒素原性 O157:H7 およびその他の病原体を含む大腸菌の抑制
臨床試験における１日の投与量
 1) LP01 5 billion CFU + BR03 5 billion CFU
 2) LP01 5 billion CFU/strain vs.BR03 1 billion cells/strain
 3, 4) LP01 2.5 billion CFU + BR03 2.5 billion CFU
 5) 10 billion CFU
 *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Saggioro A. Probiotics in the treatment of Irritable Bowel Syndrome. J Clin Gastroenterol, 2004; 38(8): S104-106.
  2. Del Piano et al. Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison to the same uncoated strains. J Clin Gastroenterol, 2010; 44(8):S42-46.
  3. Del Piano M. et al. The use of probiotics in healthy volunteers with evacuation disorders and hard stools. A double blind, randomized, placebocontrolled study. J Clin Gastroenterol, 2010; 44(8): S30-34.
  4. Dimidi E. et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;100:1075–84.
  5. Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly (BL03, LP01, BS01, LR05, BA02 and BR03 seperately). CIBUS, 2005; 1(1):23-30.
 インビトロ研究
  1. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
  2. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
  3. Amoruso A. et al. (2019) A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 7:214.
  4. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.
 腸管透過性に関するインビトロの内部データはご要望に応じて入手可能です。

Lactiplantibacillus plantarum LP01™ (LMG P-21021)
(旧名 Lactobacillus plantarum)
Lactobacillus acidophilus LA02 (DSM 21717)
PROBIAL® Flatt Belly
機能性ƒ
  • IBS
  • 胃腸の不快感の軽減
  • 炎症の軽減
  • 抗病原体活性
臨床試験における１日の投与量
 1) LP01 5 billion CFU
 *LA-02 5 billion CFU  *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Saggioro A. Probiotics in the treatment of Irritable Bowel Syndrome. J Clin Gastroenterol, 2004; 38(8): S104-106.
 インビトロ研究
  1. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.
  2. Amoruso A. et al. (2019) A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 7:214.
  3. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
 腸管透過性および抗炎症活性に関するインビトロの内部データはご要望に応じて入手可能です。


IBD / SUDD / 便秘

Bifidobacterium longum W11 (LMG P-21586)
機能性
  • IBSに関連する胃腸の不快感の軽減
  • 腸内細菌叢のバランスを整える
  • 非伝染性リファマイシン耐性
  • エキソ多糖類の生成
臨床試験における１日の投与量
 1, 2, 3, 4, 5, 6, 7) 5 billion CFU + FOS
 8) 10 billion AFU
 *("CFU/AFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Amenta M. et al. Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight). Acta Biomed 2006; 77(3):157-62.
  2. Colecchia A. et al. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 2006; 52(4):349-58.
  3. Fanigliulo L. et al. Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomed 2006; 77(2):85-9.
  4. Sarnelli G. et al. Effects of oral supplementation with the symbiotic (Bifidobacterium longum W11 + FOS Actilight) on IBS with constipation: a randomized, dose finding trial, versus fibers. Digestive and Liver Disease 2008; 40(1):S141.
  5. Malaguarnera M. et al. Bifidobacterium longum with fructooligosaccharides (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52:3259-3265.
  6. Dughera L. et al. Effects of symbiotic preparation on constipated irritable bowel syndrome symptoms. Acta Biomed 2007; 78:111-116.
  7. Del Piano M. et al. Clinical Experience With Probiotics in the Elderly on Total Enteral Nutrition. J Clin Gastroenterol 2004;38:S111-S114.
  8. Di Pierro F. et al. Effects of rifaximin-resistant Bifidobacterium longum W11 in subjects with symptomatic uncomplicated diverticular disease treated with rifaximin. Minerva Gastroenterol Dietol. 2019 Dec; 65(4):259-264.
 インビトロ研究
  1. Graziano T. et al. The possible innovative use of Bifidobacterium longum W11 in association with rifaximin: a new horizon for combined approach? J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S153-S156.
  2. Inturri R. et al. Complete Genome Sequence of Bifidobacterium longum W11 (LMG P-21586), Used as a Probiotic Strain. Genome Announc. 2017 Mar 9;5(10). pii: e01659-16. doi: 10.1128/genome A.01659-16.
  3. Inturri R. et al. Chemical and biological properties of the novel exopolysaccharide produced by a probiotic strain of Bifidobacterium longum, Carbohydrate polymers / Elsevier 2017.
  4. Medina et al. Differential immunomodulatory properties of Bifidobacterium longum strains: relevance to probiotic selection and clinical applications, Clinical and Experimental Immunology, 2007.
  5. Izquierdo E. et al. Resistance to Simulated Gastrointestinal Conditions and Adhesion to Mucus as Probiotic Criteria for B. longum strains. Curr Microbiol 2008, 56:613-618.
  6. Interri R. et al. Scanning Electro Microscopy Observation of Adhesion Properties of B. longum W11 and Chromatographic Analysis of Its Exopolysaccharide 2014, Food and Nutrition Sciences 1787-1792.
  7. Interri R. et al. Immunomodulatory Effects of B. longum W11 Produced Exopolysaccharide on Cytokine Production. 2017, Current Pharmaceutical Biotechnology.
  8. B. longum W11, an antibiotic resistant probiotic, Di Pierro 2018, CEC online article: https://www.nutrafoods.eu/index.php/nutra/article/view/93s


下痢

Lacticaseibacillus rhamnosus LR04 (DMS 16605)
(旧名 Lactobacillus rhamnosus)
LACTARRHEA®
機能性
  • 下痢
  • 腸管出血性 O157:H7 およびその他の経路を含む大腸菌の抑制
臨床試験における１日の投与量
 1) 10 billion CFU
 2) 5 billion CFU or 1 billion cells
 *("CFU/AFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Dezi A. et al. Probiotics and chronic diarrhea in the elderly. CIBUS, 2004; 8(2):58-64.
  2. Del Piano M. et al. Comparison of the Kinetics of Intestinal Colonization by Associating 5 Probiotic Bacteria Assumed Either in Microencapsulated or in a Traditional, Uncoated Form. J Clin Gastroenterol 2012;46:S85-S92.
 インビトロ研究
  1. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
  2. Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008.
  3. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.
  4. Chamignon C et al. Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various Lactobacillus Strains. Microorganisms. 2020 Jul 15;8(7):1053.

Lacticaseibacillus rhamnosus GG (ATCC ５３１０３)
(旧名 Lactobacillus rhamnosus)
機能性
  • 下痢
  • ロタウイルス性下痢
  • 胃腸炎
  • 牛乳アレルギーを含むアレルギー
  • ADHDと自閉症の予防
  • NEC
  • 呼吸器疾患、URTI
  • 口腔の健康、虫歯
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. 世界で最も認知されているプロバイオティクス株の 1 つで、特に小児の下痢に関連しており、早産児から高齢者、妊婦まで 1,000 件を超える出版物と 300 件の臨床研究が行われています。
 医薬品有効成分 (API) としても入手可能です。

Lactiplantibacillus rhamnosus LR04 (DSM 16605)
(旧名 Lactobacillus rhamnosus)
Lactiplantibacillus reuteri LRE02 (DSM 23878)
(旧名 Lactobacillus rhamnosus)
FLOR-EN® Baby
機能性ƒ
  • 抗生物質に関連した下痢の予防
臨床試験における１日の投与量
 1) LR04 1 billion cells + LRE02 200 million cells
 *LA-02 5 billion CFU  *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Drago L, Meroni G, Chiaretti A, Laforgia N, Cucchiara S, Baldassarre ME, On Behalf Of The Surveyflor Group. Effect of LimosiLactobacillus reuteri LRE02-Lacticaseibacillus rhamnosus LR04 Combination on Antibiotic- Associated Diarrhea in a Pediatric Population: A National Survey. J Clin Med. 2020 Sep 24;9(10):E3080.
 インビトロ研究
  1. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.
  2. Chamignon C et al. Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various Lactobacillus Strains. Microorganisms. 2020 Jul 15;8(7):1053 (LR04).


短腸症候群 (Short Bowel Syndrome:SBS) / D型乳酸アシドーシス

Lacticaseibacillus rhamnosus GG (ATCC 53103)
(旧名 Lactobacillus rhamnosus)
Bifidobacterium animalis subsp. lactisBS01™ (LMG P-21384)
Bifidobacterium breveBR03™ (DSM 16604)
Bifidobacterium longumBL03 (DSM 16603)
機能性ƒ
  • 下痢
  • 腸管移動
臨床試験における１日の投与量
 1) GG 25 billion CFU + BS01 15 billion CFU + BR03 5 billion CFU + BL03 5 billion CFU
 *LA-02 5 billion CFU  *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Yilmaz B, Schibli S, Macpherson AJ, et al. D-lactic Acidosis: Successful Suppression of D-lactate–Producing Lactobacillus by Probiotics. Pediatrics. 2018;142(3):e20180337.
 インビトロ研究
  1. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012;46 Suppl.S29-32


胃腸の不快感 / PPI (プロトンポンプ阻害薬)

Lacticaseibacillus rhamnosus LR06 (DSM 21981)
(旧名 Lactobacillus rhamnosus)
Lactiplantibacillus pentosus LPS01 (DSM 21980)
(旧名 Lactobacillus pentosus)
Lactiplantibacillus plantarum LP01™ (LMG P-21021)
(旧名 Lactobacillus plantarum)
Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106)
GASTROBARRIER®
機能性
  • 胃のバリア機能
  • 口臭（口臭）の発生率と重症度の改善 – 口腔ケアのセクションを参照ください。
臨床試験における１日の投与量
 1) LR06 3 billion AFU + LPS01 3 billion AFU + LP01 3 billion AFU + LDD01 1 billion AFU + NAC
 2) LR06 3 billion AFU + LPS01 3 billion AFU+ LDD01 1 billion AFU
 3) LR06, LPS01, LP01 1.5 billion AFU + LDD01 0.5 billion AFU
 *LA-02 5 billion CFU/AFU  *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Del Piano M. et al. The Innovative Potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01 and Lactobacillus delbrueckii subsp. delbrueckii LDD01 to Restore the Gastric Barrier Effect” in Patients Chronically Treated with PPIs – a Pilot Study. J Clin Gastroenterol 2012;46:S18-S26.
  2. Del Piano M. et al. Correlation Between Chronic Treatment With Proton Pump Inhibitors (PPIs) and Bacterial Overgrowth in the Stomach – Any Possible Beneficial Role for Selected Lactobacilli? J Clin Gastroenterol 2014;48:S40-S46.
  3. Del Piano M. et al. Correlation Between Specific Bacterial Groups in the Oral Cavity and the Severity of Halitosis: any Possible Beneficial Role for Selected Lactobacilli? J Gastroint Dig Syst, 2014; 4:197.
 インビトロ研究
  1. Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106): An Innovative Strategy to Possibly Counteract Such Infections in Humans? J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S136-S139.
  2. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
  3. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.
  4. Amoruso A. et al. (2019) A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 7:214.


腸内菌叢

Bifidobacterium bifidum BB01 (DSM 22892)
Lacticaseibacillus casei LC03 (DSM 27537)
(旧名 Lactobacillus casei)
Lactobacillus delbrueckii subsp. bulgaricus LDB01 (DSM 16606)
Streptococcus thermophilus YO8 (DSM 17843)
機能性
  • 腸内菌叢を整える
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 インビトロ研究
  1. Briandet R, Mousset PY, Langella P, Lafay S, Bermúdez-Humarán LG. Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various Lactobacillus Strains. Microorganisms. 2020 Jul 15;8(7):1053 (LC03).
 これらの菌株は、その品膣ですでに認知されたプロバイオティクス菌種のため、特定の科学文献なしで提案されています。

Streptococcus thermophilus ST10 (DSM 25246)
機能性
  • 腸内でのエキソ多糖類（EPS）の生成
  • >生理学的腸管バリアの回復腸内菌叢を整える
臨床試験における１日の投与量
 1) 1 billion CFU + tara gum
 *LA-02 5 billion CFU/AFU  *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Del Piano M. et al. Assessment of the Capability of a Gelling Complex Made of Tara Gum and the Exopolysaccharides Produced by the Microorganism Streptococcus thermophilus ST10 to Prospectively Restore the Gut Physiological Barrier. A Pilot Study. J. Clin Gastroenterol, Volume 48, Supp. 1, November/December 2014.


高齢者の腸内菌叢

Lactiplantibacillus plantarum LP01™ (LMG P-21021)
Bifidobacterium animalis subs. lactis BS05 (DSM 23032)
(旧名 Lactobacillus plantarum)
Limosilactobacillus reuteri Lb26 (DSM 16341)
(旧名 Lactobacillus reuteri)
PROBIAL® Age
機能性
  • 在宅経腸栄養療法を受けている高齢者に安全で投与しやすいプロバイオティクスブレンド
可能形態　ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Orlandoni P, et al. Safety and Efficacy of Probiotic Supplementation in Reducing the Incidence of Infections and Modulating Inflammation in the Elderly with Feeding Tubes: A Pilot, Double-Blind, Placebo-Controlled Study, “IntegPRO”. Nutrients. 2021 Jan 27;13(2):391.
 インビトロ研究
  1. Mogna L. et al. Selenium and zinc internalized by Lactobacillus buchneri Lb26 (DSM 16341) and Bifidobacterium lactis Bb1 (DSM 17850): improved bioavailability using a new biological approach. J Clin Gastroenterol. 2012; 46 Suppl:S41-5.
  2. Mangiapane E. et al. An integrated proteomic and physiological approach to understand the adhesion mechanism of the probiotic Lactobacillus reuteri Lb26 DSM16341. Journal of integrated Omics, 2013.
  3. Galano E. et al. Privileged Incorporation of Selenium as Selenocysteine in Lactobacillus reuteri Proteins Demonstrated by Selenium-specific Imaging and Proteomics. Molecular & Cellular Proteomics 12.8, 2013.
  4. Mangiapane E. et al. Selenium effects on the metabolism of a Semetabolizing Lactobacillus reuteri: analysis of envelope-enriched and extracellular proteomes. The Royal Society of Chemistry, 2014.
  5. Mangiapane E. et al. Selenium and Selenoproteins: An Overview on Different Biological Systems. Current Protein and Peptide Science, 2014, 15, 598-607.


機能性ディスペプシア (FD)

Lactiplantibacillus rhamnosus LR04 (DSM 16605)
(旧名 Lactobacillus rhamnosus)
Lactiplantibacillus plantarum LP01™ (LMG P-21021)
(旧名 Lactobacillus plantarum)
Lactiplantibacillus pentosus LPS01 (DSM 21980)
(旧名 Lactobacillus pentosus)
Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106)
PROBIAL® Stomach
機能性
  • 単独または標準的な薬物療法と組み合わせて、食後ディストレス症候群の症状を軽減します
臨床試験における１日の投与量
 + LR04 1 billion cell + LPS01 0.8 billion cell + LDD01 0.2 billion cell + NAC
 *("CFU"は非処理の菌数、"cell"はマイクロカプセル化菌数)
可能形態　ブレンド原体、あるいは製剤
学術サポート
 ヒト臨床試験
  1. Orlandoni P, et al. Safety and Efficacy of Probiotic Supplementation in Reducing the Incidence of Infections and Modulating Inflammation in the Elderly with Feeding Tubes: A Pilot, Double-Blind, Placebo-Controlled Study, “IntegPRO”. Nutrients. 2021 Jan 27;13(2):391.


抗病原体活性

Lactiplantibacillus plantarum LP01™ (LMG P-21021)
(旧名 Lactobacillus plantarum)
Lactiplantibacillus plantarum LP02<(LMG P-21020)
(旧名 Lactobacillus plantarum)
Lacticaseibacillus rhamnosus LR04 (DSM 16605)
(旧名 Lactobacillus rhamnosus)
Lacticaseibacillus rhamnosus LR06 (DSM 21981)
(旧名 Lactobacillus rhamnosus)
Lactiplantibacillus pentosus LPS01 (DSM 21980)
(旧名 Lactobacillus pentosus)
Bifidobacterium breve BR03™ (DSM 16604)
機能性
  • 大腸菌の抑制
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 インビトロ研究
  1. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
  2. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216. Orlandoni P, et al. Sa

Lactobacillus delbrueckii subsp. Delbrueckii LDD01 (DSM 22106)
(旧名 Lactobacillus plantarum)
機能性
  • 腸管出血性O157:H7を含む大腸菌の抑制
  • 肺炎桿菌および疝痛のある乳児から分離されたさまざまな大腸菌群の抑制
可能形態　ブレンド原体、あるいは製剤
学術サポート
 インビトロ研究
  1. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
  2. Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106): An Innovative Strategy to Possibly Counteract Such Infections in Humans? J. Clin Gastroenterol. 2016 Nov/Dec; 50 Suppl 2.
  3. Savino F. et al. Antagonistic effect of Lactobacillus strains against gasproducing coliforms isolated from colicky infants. BMC Microbiology 2011, 11:157

Lactiplantibacillus plantarum LP01™ (LMG P-21021)
(旧名 Lactobacillus plantarum)
Lacticaseibacillus rhamnosus LR04 (DSM 16605)
(旧名 Lactobacillus rhamnosus)
Lactobacillus acidophilus LA02 (DSM 21717)
Limosilactobacillus reuteri LRE02
可能形態　単体原体、ブレンド原体、あるいは製剤
Lactiplantibacillus plantarum LP14 (DSM 33401)
(旧名 Lactobacillus plantarum)
Limosilactobacillus fermentum LF26 (DSM 33402)
(旧名 Lactobacillus fermentum)
Lacticaseibacillus casei LC04 (DSM 33400)
(旧名 Lactobacillus casei)
Ligilactobacillus salivarius LS01™ (DSM 22775)
(旧名 Lactobacillus salivarius)
Lacticaseibacillus paracasei LPC09 (DSM 24243)
(旧名 Lactobacillus paracasei)
可能形態　ブレンド原体、あるいは製剤
機能性
  • 病原性大腸菌、大腸菌、肺炎桿菌、黄色ブドウ球菌および/または緑膿菌の抑制
学術サポート
 インビトロ研究
  1. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.

Limosilactobacillus reuteri LRE02 (DSM 23878)
(旧名 Lactobacillus reuteri)
機能性
  • ロイテリンとビタミンB12の生成
  • 抗病原体活性と免疫刺激
  • 下痢
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 インビトロ研究
  1. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.

Lactiplantibacillus plantarum LP09 (DSM 25710)
(旧名 Lactobacillus plantarum)
機能性
  • 抗病原体活性
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 内部データはご要望に応じて入手可能です。

Bifidobacterium breve BR03™ (DSM 16604)
機能性
  • ガス状疝痛
  • 病原性大腸菌の抑制
  • 疝痛のある乳児から分離された腸内細菌科および他の大腸菌群の抑制
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 インビトロ研究
  1. Aloisio I. et al. Characterization of Bifidobacterium spp. strains for the treatment of enteric disorders in newborns. Appl Microbiol Biotechnol 2012, 96:1561–1576.
  2. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32.
  3. Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J. Clin. Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008.
  4. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47. Refer to the section on baby colics and on celiac disease for published clinical trials

Limosilactobacillus fermentum LF5 (CNCM I-789)
(旧名 Lactobacillus fermentum)
Limosilactobacillus fermentum LF09 (DSM 18298)
(旧名 Lactobacillus fermentum)
Limosilactobacillus fermentum LF10 (DSM 19187)
(旧名 Lactobacillus fermentum)
Limosilactobacillus fermentum LF11 (DSM 19188)
(旧名 Lactobacillus fermentum)
機能性
  • 病原性カンジダ種の抑制
可能形態　ブレンド原体、あるいは製剤
学術サポート
 インビトロ研究
  1. Deidda F. et al. The In Vitro Effectiveness of Lactobacillus fermentum Against Different Candida Species Compared With Broadly Used Azoles. 2016 J Clin Gastroenterol 50:S171-S174.

Ligilactobacillus salivarius CRL1328 (DSM 24441)
(旧名 Lactobacillus salivarius)
 アルゼンチンの CEntro de REferencia para LActobacilos から世界規模の独占的ライセンスを受けています
機能性
  • エンテロコッカス・フェカリス、エンテロコッカス・フェシウムおよび淋菌の抑制
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 インビトロ研究
  1. Ocana V. et al. Characterization of a bacteriocin like substance produced by a vaginal Lactobacillus salivarius strain. Applied and Environmental Microbiology, 1999; 65(12):5631-5635

Lacticaseibacillus rhamnosus LR04 (DSM 16605)
(旧名 Lactobacillus rhamnosus)
機能性
  • 肺炎桿菌および大腸菌の抑制
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 インビトロ研究
  1. Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106). An Innovative Strategy to Possibly Counteract Such Infections in Humans? J Clin Gastroenterol, Vol 50, Supp. 2, November/December 2016.
  2. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
  3. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.
 特定の菌株については、ご要望に応じて免疫刺激および抗病原体活性に関する内部データが利用可能です。

Lacticaseibacillus rhamnosus LR06 (DSM 21981)
(旧名 Lactobacillus rhamnosus)
機能性
  • オキサシリン耐性およびメチシリン耐性黄色ブドウ球菌の定着を阻止する能力
可能形態　単体原体、ブレンド原体、あるいは製剤
学術サポート
 インビトロ研究
  1. Squarzanti DF, et al. Il surnatante di Lactobacillus johnsonii LJO02 coltivato in un terreno vegetale contrasta la virulenza del patogeno opportunista Staphylococcus aureus. Poster from the XIX CONGRESSO NAZIONALE CSID, held in Novara on 1-2 October, 2022.

Lactiplantibacillus plantarum LP14 (DSM 21981)
(旧名 Lactobacillus plantarum)
Lactobacillus acidophilus LA06 (DSM 23033)
Lactobacillus crispatus LCR04 (DSM 33487)
可能形態　ブレンド原体、あるいは製剤
Lactobacillus acidophilus LA02 (DSM 21717)
Lactiplantibacillus plantarum LP01™ (LMG P-21021)
(旧名 Lactobacillus plantarum)
Lactiplantibacillus plantarum LP02 (LMG P-21020)
(旧名 Lactobacillus plantarum)
Lactiplantibacillus pentosus LPS01 (DSM 21980)
(旧名 Lactobacillus pentosus)
Levilactobacillus brevis LBR01 (DSM 23034)
(旧名 Lactobacillus brevis)
可能形態　単体原体、ブレンド原体、あるいは製剤
機能性
  • 生体アミン、重金属、グリホサートの解毒
学術サポート
 インビトロ研究
  1. lactobacillus probiotic strains. Poster from the 12th Probiotics, Prebiotics & New Foods, Nutraceutical and Botanicals for Nutrition & Human and Microbiota Health, held in Rome on 12-14 September 2021.
採用情報

プライバシーマーク